SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Ranbaxy Laboratories
Ranbaxy Laboratories
BSE: 500359|NSE: RANBAXY|ISIN: INE015A01028|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Apr 01, 17:00
859.90
0
VOLUME 308,222
Ranbaxy Laboratories is not traded in the last 30 days
News on Ranbaxy Laboratories
Select Year: 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Pharma's open offer for Zenotech stake gets tepid response

9.50 pm | 24 Jul 2015 |  Source: PTI

Drug major Sun Pharmaceutical's open offer to acquire 28.16 percent stake in Zenotech Laboratories elicited tepid response from the shareholders. ...

What took mighty Lupin down! 

3.46 pm | 24 Jul 2015 |  Source: CNBC-TV18

In an interview with CNBC-TV18’s Sonia Shenoy & Latha Venkatesh, Praful Bohra, VP- Research, Religare said that Lupin’s numbers are weak due to de...

Wait 2-3 qtrs to buy Lupin, Sun Pharma: Prabhudas Lilladher

2.02 pm | 24 Jul 2015 |  Source: CNBC-TV18

Pharma Analyst Surajit Pal is not very keen on holding pharma biggies, given the newsflows that are associated with them. Lupin first quarter earnings...

Here are some top trading ideas from Kunj Bansal 

10.16 am | 23 Jul 2015 |  Source: CNBC-TV18

Watch the interview of Kunj Bansal of Centrum Wealth Management with Latha Venkatesh & Sonia Shenoy on CNBC-TV18, in which he shared his readings and ...

Adopt bottoms-up approach; Sun Pharma a good buy: Pros 

4.25 pm | 21 Jul 2015 |  Source: CNBC-TV18

Despite the fall in Sun Pharma on the back of Monday's profit warnings, Parag Thakkar of HDFC Securities and Devang Mehta of Anand Rathi Financial Ser...

Accumulate Sun Pharma with 18-24 months view: Devang Mehta 

3.55 pm | 21 Jul 2015 |  Source: CNBC-TV18

Devang Mehta of Anand Rathi Financial Services recommends accumulating Sun Pharmaceutical Industries with a view of 18-24 months....

Stay away from Sun Pharma, Bharti Airtel, say experts

9.23 am | 21 Jul 2015 |  Source: CNBC-TV18

Dipan Mehta and Prakash Diwan do not think Sun Pharma is currently a great investment....

Ranbaxy integration impact to be controlled from FY17: Sun 

10.08 pm | 20 Jul 2015 |  Source: CNBC-TV18

Supply disruptions from Sun Pharma's Halol facility are also expected to continue for some more time. But the company did not give any timeline for th...

Sun Pharma issues profit warning for FY16

6.27 pm | 20 Jul 2015 |  Source: CNBC-TV18

The consolidated profit in addition to revenue may also be adversely impacted due to certain expenses/ charges arising out of integration and remedial...

Sun Pharma redoing Ranbaxy contract mfg unit, to halve size 

11.29 am | 16 Jul 2015 |  Source: CNBC-TV18

Sources say this to be a natural fallout of Sun’s stated intent to bring back all outsourced products to in-house facilities, and in turn leaving th...

Stocks in news: Tata Motors, Sobha, Rel Power, Hindalco

8.10 am | 07 Jul 2015 |  Source: CNBC-TV18

Tata Motors | Mahindra Holidays | Bosch | Prestige Estates | Maruti Suzuki | Force Motors | Neyveli Lignite | SKS Microfinance | Network 18 | Sobha | ...

Pharma's struggle to cope standards paves way for M&A deals

10.29 am | 29 Jun 2015 |  Source: Reuters

Many of its top firms are facing sanctions at some of their factories, as the US Food and Drug Administration (FDA) tightens checks and its approvals ...

See Nifty at 9300 in 2-3 months; buy RIL, SBI on dips: Pros 

3.25 pm | 27 Jun 2015 |  Source: CNBC-TV18

Jai Bala of 1857 Advisors is bullish on the Nifty and sees it at 9300 from a two to three months timeframe. According to him, it would be great if Nif...

Integration costs to continue into FY16: Sun Pharma 

1.19 pm | 01 Jun 2015 |  Source: CNBC-TV18

Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking...

Sun will turn Ranbaxy profitable; stock fall brief: Angel 

1.04 pm | 01 Jun 2015 |  Source: CNBC-TV18

Sarabjit Kaur Nangra of Angel Broking is neutral on Cipla as of now because the price has run up ahead of fundamentals....

Ranbaxy effect playing on Sun Pharma's margins: Pros 

7.18 pm | 29 May 2015 |  Source: CNBC-TV18

Sarabjit Kour Nangra, VP- Research, Angel Broking, believes it to be the Ranbaxy effect. However, she says 14.5 percent is very low, because after con...

Sun Pharma Q4 profit seen up 9.7%, sales may rise 16%: Poll 

5.02 pm | 28 May 2015 |  Source: CNBC-TV18

Drug major Sun Pharmaceutical Industries's fourth quarter consolidated profit is likely to increase 9.7 percent year-on-year to Rs 1,659.85 crore, acc...

Sun Pharma maintains 13-15% FY15 topline guidance: CFO 

2.54 pm | 18 Feb 2015 |  Source: CNBC-TV18

The company has grown faster than the market in India and would be focused on research and development (R&D) spends going forward, said Uday Baldota, ...

Operating performance may hurt Sun Pharma's Q3 profit: Poll

2.46 pm | 13 Feb 2015 |  Source: Moneycontrol.com

Sun Pharmaceutical Industries will announce its third quarter earnings on Saturday. According to a CNBC-TV18 poll, net profit of the drug maker may ri...

Buy Ranbaxy Labs; target of Rs 800: Motilal Oswal

4.52 pm | 30 Jan 2015 |  Source: Moneycontrol.com

Brokerage house Motilal Oswal is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target price of Rs 800, in its res...

1 2 3
Quick Links for Ranbaxy Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.